ALPS Medical Breakthrough

Mirum Pharmaceuticals Launches $600M Convertible Senior Note Private Placement

UBS Maintains Buy Rating on CG Oncology with $90 Target Price Based on Bladder Cancer Therapy Data

LifeSci Capital Analyst Slutsky Reaffirms Buy Rating on SYRE with $103 Price Target

CG Oncology Plans Q4 BLA Submission for Bladder Cancer Drug Cretostimogene

CG Oncology Announces 92.3% Complete Response Rate in Bladder Cancer Drug Trial

Celcuity released FY2026 Q1 earnings on May 14 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9702 (forecast USD -1.0636)

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Celcuity Inc. Expands Gedatolisib Phase III Trial and Receives FDA Priority Review Designation

Mirum Pharmaceuticals Issues $600 Million Convertible Senior Notes Offering

Alkermes Announces Positive Top-Line Results for Lumryz® in Adult Idiopathic Hypersomnia Phase III Study

Apogee Therapeutic released FY2026 Q1 earnings on May 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.0637 (forecast USD -1.0822)

CG Oncology released FY2026 Q1 earnings on May 8 (EST), actual revenue USD 1.083 M (forecast USD 453.03 K), actual EPS USD -0.7122 (forecast USD -0.5677)

Michael Thomas Henderson sold 80,000 shares of Spyre Therapeutics

Apellis Pharma released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 268.3 M (forecast USD 203.29 M), actual EPS USD 0.1461 (forecast USD -0.3526)

Newamsterdam Pharma released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 3.04 M (forecast USD 1.061 M), actual EPS USD -0.4 (forecast USD -0.4689)

Xenon Pharma released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 0 (forecast USD 1 M), actual EPS USD -1.1712 (forecast USD -1.1871)

Celcuity to Release FY2026 Q1 Earnings on May 14 After-Market EST, Forecast EPS USD -1.0636

Mirum Pharmaceuticals released FY2026 Q1 earnings on May 6 After-Market EST, actual revenue USD 159.88 M (forecast USD 153.05 M), actual EPS USD -13.4299 (forecast USD -0.3655)

Celcuity director Richard E. Buller sells 9,000 shares of company stock

Mirum Pharmaceuticals Reports 43% Increase in Net Product Sales in Q1 and Raises Full-Year Sales Guidance

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Pinned News

置顶新闻

Barclays Remains a Buy on Bayer (0P6S)

BAYRY

SBIO

LABU

Barclays analyst Charles Pitman maintained a Buy rating on Bayer with a price target of €50.00. Pitman has a 4-star rating with an average return of 11.4%. UBS also rated Bayer as a Buy, while Deutsche Bank issued a Hold rating on the same day.

Tip Ranks

Bayer

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

iShares US Pharma

SPDR S&P Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Barclays

Bayer Aktiengesellschaft

UBS Group AG

Deutsche Bank AG

Bayer AG

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

NBIX

SLNO

ARKG

Neurocrine Biosciences, Inc. presented new findings on INGREZZA's impact on mild tardive dyskinesia at the APA 2026 meeting, showing significant improvements in patient functional status. The company also completed its acquisition of Soleno Therapeutics for $2.9 billion, enhancing its rare disease portfolio. INGREZZA is FDA-approved for treating tardive dyskinesia and chorea associated with Huntington's disease. Neurocrine's stock closed at $157.21, down 0.76%, but rose 0.50% in after-hours trading.

nasdaq

Neurocrine Biosciences

Soleno Therapeutics

Ark Genomic Revolution ETF

VG Health

Goldman Sachs

Nasdaq

GS Hldg R

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal

BAYN

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

ORKA

IBBQ

Oruka Therapeutics SVP Arjun Agarwal sold 10,290 shares at $59.07 each, totaling $607,830.30, representing a 38.55% decrease in his ownership. Post-sale, he holds 16,406 shares valued at $969,102.42. The transaction was made under a Rule 10b5-1 plan and disclosed to the SEC. The stock is currently trading down 5.8% at $58.34.

Market Beat

Oruka Therapeutics

Invesco Nasdaq Biotechnology ETF

ROYAL BANK OF CANADA

Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $607,830.30 in Stock

SBFMW

SBFM

Sunshine Biopharma Inc. has priced a $6 million public offering, consisting of 12 million common units at $0.50 each, sending shares up 79.51% to $0.51. The offering includes Series C warrants exercisable at $0.50 for five years. Proceeds will support corporate purposes and working capital. The company markets 60 generic drugs in Canada and plans to launch 12 more in 2026, while advancing proprietary programs targeting oncology and SARS-related coronaviruses.

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

Sunshine Biopharma Prices $6M Offering; Closing May 19

BMRN

BioMarin’s BMN 401 raised plasma PPi over 52 weeks in children but showed no meaningful rickets or growth improvement. Shares fell about 3% to ~$50.10 after the announcement.12HC Wainwright & Co. reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (BMRN) and lowered its price target for the stock from $55.00 to $50.00 per share.3

TradingView

BioMarin Pharma

Key facts: BMN 401 Raises Plasma PPi; No Rickets/Growth Benefit; PT $50

RHHBY

Genentech presented new clinical data for giredestrant, an oral breast cancer drug, ahead of the ASCO 2026 meeting. The Phase III lidERA study will assess benefits across pre- and post-menopausal patients, supporting an FDA submission. Results from the persevERA study, despite missing its main goal, show numerical improvement in endocrine-sensitive disease. Additional analyses from the evERA trial will extend evidence for giredestrant in advanced breast cancer. Early safety and efficacy data for a HER2-targeted therapy will also be presented.

PUBT

Roche

Genentech says Phase III lidERA data support giredestrant in early ER+ breast cancer

VRAX

Virax Biolabs (VRAX) shares surged 17.36% to $0.28 in after-hours trading, following a 53.09% intraday gain. Armistice Capital disclosed a 4.99% stake in VRAX. The company is advancing ViraxImmune, targeting post-acute infection syndromes. Despite a market cap of $4.79 million, VRAX's stock has dropped 78.04% over the past year, trading closer to its 52-week low of $0.10.

fidelity

Bakkt

BAKKT INC C/WTS 25/10/2026 (TO PUR COM)

Why Is Virax Biolabs (VRAX) Stock Trending Overnight?

RVPH

OTC Markets Group has approved Reviva Pharmaceuticals, along with Uraniumx Discovery and zSpace, to begin trading on its OTCQB Venture Market starting May 18.

Reviva Pharmaceuticals

Zspace

Reviva Pharmaceuticals - CW23

OTC Markets approves Reviva Pharmaceuticals for trading on OTCQB Venture Market

ABCL

AbCellera Biologics reported Q1 2026 results with revenue at $8.32 million and a net loss of $43.17 million. The company is advancing ABCL635 into Phase II for nonhormonal menopause therapy, indicating a shift towards internal clinical assets. Analysts project $123.3 million in revenue by 2028, with a fair value estimate of $9.83, suggesting a 136% upside. However, ongoing losses and reliance on internal programs pose risks to investors.

Simplywall

Abcellera Biologics

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Is AbCellera (ABCL) Quietly Rewriting Its Business Model With ABCL635’s Phase II Menopause Bet?

ATYR

RBC Capital has maintained a Hold rating on aTyr Pharma (ATYR) with a price target of $1.00, while the shares closed at $0.50. Analyst Brian Abrahams has an average return of 10.7% and a 52.10% success rate. Wells Fargo also issued a Hold rating, while Piper Sandler maintained a Buy rating on May 12.

ATYR Pharma

Gilead Sciences

Regeneron Pharma

Biogen

Wells Fargo

Piper Sandler Cos

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)

ATRA

Rosen Law Firm is reminding investors who purchased Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, of the May 22, 2026, lead plaintiff deadline for a securities fraud lawsuit. Investors may be entitled to compensation without upfront fees. The lawsuit alleges that Atara made misleading statements regarding manufacturing issues and regulatory prospects, leading to investor damages when the truth emerged.

prnewswire

Atara Biotherap

21:12 ETATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

Novo Nordisk AS

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bear 1X Shares

Eli Lilly

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

ALPS Medical Breakthrough(SBIO.US)

Barclays Remains a Buy on Bayer (0P6S)

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $607,830.30 in Stock

Sunshine Biopharma Prices $6M Offering; Closing May 19